Atorvastatin and Hesperidin: A Study into Their Effect on the Liver
,
Abstract
The liver is a vital organ responsible for metabolism, immune support, and detoxification, making it vulnerable to drug-induced injuries that can lead to severe complications. Among commonly prescribed medications, atorvastatin is effective in lowering cholesterol levels and reducing cardiovascular disease risk but can also cause hepatotoxicity. This study aims to investigate the potential hepatoprotective effects of hesperidin, a flavonoid known for its antioxidant properties, against liver damage caused by atorvastatin. By examining changes in liver enzyme levels, particularly ALT and AST, the research seeks to elucidate hesperidin's role in mitigating statin-induced liver injury. This study utilized thirty healthy male Wistar rats, aged 10 to 12 weeks and weighing approximately 230 grams, housed under standardized conditions at Mustansiriyah University. The rats had unlimited access to tap water and pellet food, with all care methods approved by the university's ethical committee. Atorvastatin and hesperidin were sourced from AstraZeneca (Germany) and a supplier in China, respectively, and dissolved in DMSO for administration. The rats were randomly divided into five groups, with varying treatments over twenty days, including a negative control group receiving saline and groups receiving atorvastatin alone or in combination with different doses of hesperidin. Blood samples were collected for liver enzyme analysis (ALT and AST) following ethical guidelines. Data was analyzed using SPSS software, with significance determined at a P less than 0.05. The results indicated significant differences in liver enzyme levels among the experimental groups (P<0.05). Group 2, which received 80 mg/kg atorvastatin, exhibited markedly elevated ALT and AST levels compared to the negative control group. In contrast, groups receiving hesperidin in combination with atorvastatin showed significant declines in both ALT and AST levels. Notably, Group 3 (80 mg/kg atorvastatin plus 50 mg/kg hesperidin) demonstrated a significant reduction in ALT compared to Group 2, while Group 5 (200 mg/kg hesperidin plus atorvastatin) exhibited the lowest ALT and AST levels overall. These findings suggest that hesperidin effectively mitigates atorvastatin-induced hepatotoxicity. Thus, incorporating hesperidin may offer a protective strategy against liver damage associated with statin therapy, warranting further investigation into its clinical applications.
2. Saravani K, Ostadrahimi P, Jahanifard A. Evaluation of the level of liver enzymes and its relationship with ferritin and the frequency of blood transfusion in patients with thalassemia. Cell Mol Biomed Rep 2024;4:100-10.
3. Reddy KTK, Reddy AS. Recent breakthroughs in drug delivery systems for targeted cancer therapy: an overview. Cell Mol Biomed Rep 2025;5:13-27.
4. McGill MR, Jaeschke H. Animal models of drug-induced liver injury. Biochim Biophys Acta Mol Basis Dis 2019;1865:1031-9.
5. Sasani S, Rashidi Monfared S, Mirzaei AR. Identification of some Echinophora platyloba miRNAs using computational methods and the effect of these miRNAs in the expression of TLN2 and ZNF521 genes in different human body organs. Cell Mol Biomed Rep 2024;4:43-53.
6. Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 2010;376:1670-81.
7. Wong ND, Levy D. Legacy of the Framingham Heart Study: rationale, design, initial findings, and implications. Glob Heart. 2013;8:3-9.
8. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992;2:23-8.
9. Law MR, Wald NJ, Thompson S. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-72.
10. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation 2014;129:S1-S45.
11. Garg A, Garg S, Zaneveld L, Singla A. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 2001;15:655-69.
12. Al-Rikabi R, Al-Shmgani H, Dewir YH, El-Hendawy S. In vivo and in vitro evaluation of the protective effects of hesperidin in lipopolysaccharide-induced inflammation and cytotoxicity of cell. Molecules 2020;25:478.
13. Jean T, Bodinier MC. Mediators involved in inflammation: effects of Daflon 500 mg on their release. Angiology 1994;45:195-200.
14. Jawad MR, Jasim GA. Biochemical and histopathological evaluation of prostatic tissue under effect of pterostilbene in benign prostatic hyperplasia rat model. Al Mustansiriyah J Pharm Sci 2023;23:196-213.
15. Alghulami OMM, Jasim GA, Jasim SY. Histopathological evaluation of docetaxel effects in treatment of rheumatoid arthritis induced in rat model. Al Mustansiriyah J Pharm Sci 2023;23:168-79.
16. Coelho AM, Queiroz IF, Perucci LO, Souza MO, Lima WG, Talvani A, et al. Piperine as therapeutic agent in paracetamol-induced hepatotoxicity in mice. Pharmaceutics 2022;14:1831.
17. Poorbagher MRM, Karimi E, Oskoueian E. Hepatoprotective effect of nanoniosome loaded Myristica fragrans phenolic compounds in mice-induced hepatotoxicity. J Cell Mol Med 2022;26:5517-27.
18. Ali YA, Soliman HA, Abdel-Gabbar M, Ahmed NA, Attia KAA, Shalaby FM, et al. Rutin and hesperidin revoke the hepatotoxicity induced by paclitaxel in male Wistar rats via their antioxidant, anti-inflammatory, and antiapoptotic activities. Evid Based Complement Alternat Med 2023;2023:2738351.
19. Li X, Lin Q, Gou F, Zhu J, Yu M, Hong Q, et al. Effects of hesperidin on mitochondrial function, mitochondria-associated endoplasmic reticulum membranes and IP3R-MCU calcium axis in the intestine of piglets exposed to deoxynivalenol. Food Funct 2024;15:6459-74.
20. Liu Y, Cheng Z, Ding L, Fang F, Cheng KA, Fang Q, et al. Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther 2010;48:798-802.
21. Taleb MH, Almasri IM, Siam NI, Najim AA, Ahmed AI. The effect of atorvastatin on liver function among patients with coronary heart disease in Gaza strip. Pharmacol Pharm 2014;5:781-8.
22. Hanchang W, Wongmanee N, Yoopum S, Rojanaverawong W. Protective role of hesperidin against diabetes-induced spleen damage: mechanism associated with oxidative stress and inflammation. J Food Biochem 2022;46:e14444.
23. Nasehi Z, Kheiripour N, Taheri MA, Ardjmand A, Jozi F, Shahaboddin ME. Efficiency of hesperidin against liver fibrosis induced by bile duct ligation in rats. Biomed Res Int 2023;2023:5444301.
24. Adedara AO, Bressan GN, Dos Santos MM, Fachinetto R, Abolaji AO, Barbosa NV. Antioxidant responses driven by hesperetin and hesperidin counteract Parkinson's disease-like phenotypes in Drosophila melanogaster. Neurotoxicology 2024;101:117-27.
25. Moriles KE, Azer SA. Alanine aminotransferase 2020.
26. Ebrahimi R, Sepand MR, Seyednejad SA, Omidi A, Akbariani M, Gholami M, et al. Ellagic acid reduces methotrexate-induced apoptosis and mitochondrial dysfunction via up-regulating Nrf2 expression and inhibiting the IκBα/NFκB in rats. DARU J Pharm Sci 2019;27:721-33.
27. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:S77-S81.
28. Bays H, Cohen DE, Chalasani N, Harrison SA. An assessment by the statin liver safety task force: 2014 update. J Clin Lipidol 2014;8:S47-S57.
29. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20.
30. Cheraghpour M, Imani H, Ommi S, Alavian SM, Karimi-Shahrbabak E, Hedayati M, et al. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled, double-blind clinical trial. Phytother Res 2019;33:2118-25.
31. Chen H, Nie T, Zhang P, Ma J, Shan A. Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation. Life Sci 2022;296:120428.
| Files | ||
| Issue | Vol 63 No 3 (2025) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/acta.v63i3.19719 | |
| Keywords | ||
| Hepatotoxicity Atorvastatin Hesperidin Liver Enzymes Antioxidant Properties | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
